REG - Goldman Sachs & Co. - 38.5b - Horizon Therapeutics plc

Sanofi SAAnnouncement

06/12/2022 12:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221206:nRSF7788Ia&default-theme=true

RNS Number : 7788I  Goldman Sachs & Co. LLC  06 December 2022

 
FORM 38.5(b)

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITHOUT RECOGNISED INTERMEDIARY STATUS, OR WITH RECOGNISED INTERMEDIARY STATUS BUT NOT DEALING IN A CLIENT-SERVING CAPACITY

 

1. KEY INFORMATION

 

 Name of exempt principal trader                                          GOLDMAN SACHS & CO. LLC
 Company dealt in                                                         HORIZON THERAPEUTICS PLC
 Class of relevant security to which the dealings being disclosed relate  USD 0.0001  ordinary shares
 (Note1)
 Date of dealing                                                          05 December 2022

 

2. INTERESTS AND SHORT POSITIONS

 

(a) Interests and short positions (following dealing) in the class of relevant security dealt in  (Note 2)

 

                                              Long               Short
                                              Number     (%)     Number   (%)
 (1) Relevant securities                      1,016,198  (0.44)  616,607  (0.27)
 (2) Derivatives (other than options)         0          (0.00)  0        (0.00)
 (3) Options and agreements to purchase/sell  0          (0.00)  0        (0.00)
 Total                                        1,016,198  (0.44)  616,607  (0.27)

 

(b) Interests and short positions in relevant securities of the company, other than the class dealt in  (Note 2)

 

 Class of relevant security:                  Long         Short
                                              Number  (%)  Number  (%)
 (1) Relevant securities
 (2) Derivatives (other than options)
 (3) Options and agreements to purchase/sell
 Total

 

3.    DEALINGS (Note 3)

(a) Purchases and sales

 

 Purchase/sale                   Number of relevant securities  Price per unit  (Note 4)
 Sale (Borrow Partial Return)    20,200                         N/A
 Sale (Borrow Partial Return)    12,600                         N/A
 Sale (Borrow Partial Return)    2,200                          N/A
 Sale (Borrow Partial Return)    2,200                          N/A
 Purchase (Borrow New)           2,200                          N/A
 Purchase (Loan Partial Return)  10,474                         N/A
 Purchase (Loan Partial Return)  2,200                          N/A
 Purchase (Loan Partial Return)  5,015                          N/A
 Purchase (Borrow New)           604,704                        N/A
 Sale (Loan Adjust)              410                            N/A
 Sale (Loan Adjust)              56                             N/A
 Sale (Loan Adjust)              382                            N/A
 Purchase (Loan Partial Return)  410                            N/A
 Purchase (Loan Partial Return)  1,327                          N/A
 Purchase (Loan Partial Return)  751                            N/A
 Purchase (Loan Partial Return)  909                            N/A
 Purchase (Loan Partial Return)  382                            N/A
 Purchase (Borrow New)           599,699                        N/A
 Sale (Borrow Full Return)       599,699                        N/A
 Sale (Borrow Partial Return)    599,699                        N/A
 Sale (Borrow Partial Return)    74                             N/A
 Sale (Borrow Partial Return)    2,159                          N/A
 Sale (Borrow Partial Return)    15,274                         N/A
 Purchase (Borrow New)           2,200                          N/A
 Sale (Borrow Full Return)       5,005                          N/A

 

(b) Derivatives transactions (other than options transactions)

 

 Product name, e.g. CFD  Nature of transaction  (Note 5)   Number of relevant securities  (Note 6)   Price per unit  (Note 4)

 

(c) Options transactions in respect of existing relevant securities

 

(i) Writing, selling, purchasing or varying

 

 Product name,e.g. call option  Writing, selling,  purchasing, varying etc.   Number of securities to which the option relates  (Note 7)   Exercise price  Type, e.g. American, European etc.  Expiry date  Option money paid/received per unit  (Note 4)

 

(ii)            Exercising

 

 Product name,e.g. call option  Number of securities  Exercise price per unit  (Note 4)

 

(d)            Other dealings (including transactions in respect of new securities)  (Note 3)

 

 Nature of transaction  (Note 7)   Details  Price per unit (if applicable)  (Note 4)

 

4. OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

 Full details of any agreement, arrangement or understanding between the person
 disclosing and any other person relating to the voting rights of any relevant
 securities under any option referred to on this form or relating to the voting
 rights or future acquisition or disposal of any relevant securities to which
 any derivative referred to on this form is referenced.  If none, this should
 be stated.
 NONE

 

Is a Supplemental Form 8 attached? (Note 9)        NO

 

 Date of disclosure                            06 December 2022
 Contact name                                  Papa Lette and Andrzej Szyszka
 Telephone number                              +33(1) 4212 1459 / +48(22) 317 4817
 Name of offeree/offeror with which connected  Sanofi
 Nature of connection (Note 9)                 Advisor to Offeror

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ISEUNSARUAUURAA